Free Trial

Marpai (MRAI) Competitors

$0.90
-1.04 (-53.61%)
(As of 05/28/2024 ET)

MRAI vs. OTRK, MGRX, BRTX, GBNHF, SGRP, CCRC, SREV, CLOV, DVA, and FMS

Should you be buying Marpai stock or one of its competitors? The main competitors of Marpai include Ontrak (OTRK), Mangoceuticals (MGRX), BioRestorative Therapies (BRTX), Greenbrook TMS (GBNHF), SPAR Group (SGRP), China Customer Relations Centers (CCRC), ServiceSource International (SREV), Clover Health Investments (CLOV), DaVita (DVA), and Fresenius Medical Care (FMS).

Marpai vs.

Marpai (NASDAQ:MRAI) and Ontrak (NASDAQ:OTRK) are both small-cap business services companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

49.8% of Marpai shares are held by institutional investors. Comparatively, 13.0% of Ontrak shares are held by institutional investors. 61.3% of Marpai shares are held by company insiders. Comparatively, 1.6% of Ontrak shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Marpai has a net margin of -69.48% compared to Ontrak's net margin of -186.35%. Marpai's return on equity of 0.00% beat Ontrak's return on equity.

Company Net Margins Return on Equity Return on Assets
Marpai-69.48% N/A -68.67%
Ontrak -186.35%-304.29%-107.05%

Marpai currently has a consensus target price of $6.00, indicating a potential upside of 566.67%. Ontrak has a consensus target price of $4.00, indicating a potential upside of 1,468.63%. Given Ontrak's higher possible upside, analysts plainly believe Ontrak is more favorable than Marpai.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marpai
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Ontrak
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Marpai has a beta of 5.39, suggesting that its share price is 439% more volatile than the S&P 500. Comparatively, Ontrak has a beta of 2.5, suggesting that its share price is 150% more volatile than the S&P 500.

Ontrak received 35 more outperform votes than Marpai when rated by MarketBeat users. However, 66.67% of users gave Marpai an outperform vote while only 58.73% of users gave Ontrak an outperform vote.

CompanyUnderperformOutperform
MarpaiOutperform Votes
2
66.67%
Underperform Votes
1
33.33%
OntrakOutperform Votes
37
58.73%
Underperform Votes
26
41.27%

Ontrak has lower revenue, but higher earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Ontrak, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marpai$37.15M0.25-$28.75M-$3.19-0.28
Ontrak$12.74M0.96-$27.92M-$4.00-0.06

In the previous week, Marpai had 1 more articles in the media than Ontrak. MarketBeat recorded 5 mentions for Marpai and 4 mentions for Ontrak. Ontrak's average media sentiment score of 0.69 beat Marpai's score of 0.54 indicating that Ontrak is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Marpai
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Ontrak
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Marpai beats Ontrak on 10 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MRAI vs. The Competition

MetricMarpaihealth & allied services, not elsewhere classified IndustryBusiness SectorNASDAQ Exchange
Market Cap$9.28M$2.12B$6.56B$8.09B
Dividend YieldN/A2.09%3.01%3.96%
P/E Ratio-0.2816.7421.3618.43
Price / Sales0.255.90851.9972.31
Price / CashN/A12.4524.8528.77
Price / Book-0.523.864.564.39
Net Income-$28.75M$74.19M$117.64M$213.55M
7 Day Performance-54.31%-5.09%-0.48%-0.81%
1 Month Performance-58.72%-0.55%8.57%3.42%
1 Year Performance-67.81%-23.66%7.10%7.52%

Marpai Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OTRK
Ontrak
1.9466 of 5 stars
$0.26
-7.3%
$4.00
+1,468.6%
-91.0%$12.23M$12.74M-0.06102Short Interest ↑
Gap Down
MGRX
Mangoceuticals
0 of 5 stars
$0.44
+7.3%
N/A-57.7%$10.92M$730,000.000.003Short Interest ↓
BRTX
BioRestorative Therapies
2.9198 of 5 stars
$1.29
flat
N/AN/A$8.73M$150,000.00-0.3711Short Interest ↓
GBNHF
Greenbrook TMS
0 of 5 stars
$0.09
flat
N/AN/A$3.75M$73.79M0.00489
SGRP
SPAR Group
3.5779 of 5 stars
$2.59
+8.8%
N/A+119.5%$63.02M$267.06M6.3224,288Short Interest ↓
High Trading Volume
CCRC
China Customer Relations Centers
0 of 5 stars
$6.50
flat
N/A+0.0%$119.15M$240.32M0.0021,242
SREV
ServiceSource International
0 of 5 stars
$1.50
flat
N/A+0.0%$150.39M$195.70M-16.662,900
CLOV
Clover Health Investments
1.8877 of 5 stars
$1.01
+1.0%
$1.50
+48.5%
+6.4%$501.40M$2.03B-2.97552Short Interest ↓
Analyst Revision
DVA
DaVita
3.0497 of 5 stars
$143.67
+3.7%
$144.67
+0.7%
+52.4%$12.60B$12.14B16.3370,000Positive News
FMS
Fresenius Medical Care
3.6648 of 5 stars
$21.33
+0.4%
$24.00
+12.5%
-1.2%$12.52B$19.47B23.971,358Short Interest ↓
Positive News
Gap Down

Related Companies and Tools

This page (NASDAQ:MRAI) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners